Researchers at Ohio State University Wexner Medical Center correlated gene mutations with acute myeloid leukemia (AML) subgroups, identifying key mutational features and potentially important genetic differences among the subgroups. The study's findings may help guide mutation testing and treatment decisions in AML patients.
Researchers at Ohio State University Comprehensive Cancer Center have identified a mechanism by which cancer cells develop resistance to FGFR inhibitors. By inhibiting the regulatory protein Akt, they found that cell proliferation, migration, and invasion could be slowed in lung and bladder cancer cells.
The European LeukemiaNet has released updated guidelines for the diagnosis and treatment of acute myeloid leukemia (AML) in adults, including revised genetic categories and a proposed response category based on minimal residual disease status. These recommendations aim to improve patient outcomes and harmonize clinical trials.
A new classification system for glioblastoma, a lethal brain cancer, has been developed by incorporating molecular variables. The refined model significantly improves the prognosis of patients treated with radiation and temozolomide, offering better clinical decision-making options.
Regular NSAID use associated with a 66% increased risk of dying from endometrial cancer, particularly among those who had used NSAIDs for over 10 years. However, the association did not apply to more aggressive Type 2 cancers.
A statewide colorectal cancer screening study found that 16% of patients diagnosed under age 50 have an inherited genetic mutation increasing their cancer risk. The study identified a broad spectrum of mutations in early-onset colon cancer patients, including those linked to breast cancer risk.
Researchers discovered two genetic mutations in the CCND1 and CCND2 genes in a subset of acute myeloid leukemia patients. These mutations were found in 15% of patients with t(8;21) AML, making them a potential target for new therapies.
A new study found that psychosocial risk factors, such as depression and anxiety, are associated with higher readmission rates and longer hospital stays among blood cancer patients. The study suggests that upfront assessment of patients' ability to cope and social support can improve recovery post treatment.
Researchers discovered how lung's immune environment enables cancer to spread to the organ. Blocking oxygen-sensing proteins may enhance T-cell responses against cancer and limit metastasis.
New research links specific inherited genetic differences to an increased risk for eye melanoma, a rare form of melanoma arising from pigment cells that determine eye color. Genetic mutations associated with skin melanoma were also found to be linked to uveal melanoma risk.
Researchers found that blocking PRMT5 forces resistant brain-tumor cells into senescence, slowing or stopping tumor growth. This approach may offer a new treatment option for patients with glioblastoma.
A new study reveals how retroviral DNA insertion complexes hunt for suitable spots and insert rapidly, with search times exceeding 2-3 seconds and insertion happening in under half a second at chosen sites. The findings could improve treatments for HIV infection and make gene therapy safer and more efficient.
Researchers at Ohio State University found that SPF30 sunscreens delayed melanoma onset in a mouse model by 80% when applied prior to UVB light exposure. The study suggests the potential of these sunscreens as effective melanoma-preventing agents.
Patients with grade 2 gliomas treated with radiation therapy plus chemotherapy had a better overall survival of 13.3 years compared to 7.8 years without chemotherapy. The study also found that patients with IDH1 mutation had significantly better overall survival regardless of treatment.
Researchers at Ohio State University Wexner Medical Center have identified altered metabolism of methionine and tryptophan as a driving force behind glioblastoma progression. Restricting dietary intake of these amino acids may slow tumor growth and improve treatment outcomes.
A new study found that low expression of SMARCA4/BRG1 gene in lung tumors may indicate patients who will benefit from certain chemotherapy regimens. The findings suggest an alternative therapy for these patients to spare them from cisplatin's side effects and allow them to try a different treatment sooner.
Researchers at Ohio State University have engineered new calcium receptors to enhance or preserve heart function in mice without harmful effects. The study shows improved cardiovascular performance and reduced mortality compared to control groups.
A phase I/II clinical trial found that acalabrutinib promotes high response rates and durable results in patients with relapsed chronic lymphocytic leukemia while producing minimal side effects. The drug's selective blockade of the BTK pathway may offer improved tolerability compared to other treatments.
Researchers developed nanoparticles that target and burst when exposed to near-infrared laser light, releasing therapeutic agents that alter gene activity in cancer stem cells. The study used human prostate-cancer cells and tumors, showing promise for overcoming biological barriers to gene-regulating agents.
A preclinical study finds that AR-42, an HDAC inhibitor, preserves muscle health and function while stopping life-threatening muscle wasting associated with advanced cancers. The experimental agent was shown to have a strong protective effect against tumor-associated muscle wasting in two preclinical models.
Researchers at Ohio State University discovered a key molecule that enables cancer cells to produce lipids, leading to rapid tumor growth. Blocking this molecule may slow tumor growth and provide new therapeutic strategies for glioblastoma and other cancers.
A phase 2 study found that 42% of older patients with acute myeloid leukemia (AML) can remain cancer-free after reduced-intensity stem cell transplantation, challenging traditional age-based exclusion criteria. This approach may offer improved outcomes for AML patients over 60 with otherwise well-tolerated treatments.
Researchers at Ohio State University suggest new ways to treat cancer by inhibiting overactive cancer-promoting genes and enhancing sluggish tumor-suppressor genes. The findings, published in Nature Communications and Nature Genetics, provide insights into the role of glucocorticoid receptors and epigenetic marks in cancer development.
Researchers at Ohio State University Comprehensive Cancer Center have designed an online database called CanDL to help molecular pathologists identify key cancer gene mutations. The freely accessible database includes information on 60 genes, 334 distinct variants and 169 unique matching literature references across multiple cancers.
Researchers at Ohio State University developed nanoparticles coated with chitosan that effectively target and kill cancer stem-like cells. The study found that these nanoparticles can increase the cytotoxicity of doxorubicin without systemic toxic side effects.
A new study found that patients with mutated IDH genes living with anaplastic astrocytoma had a significantly longer average lifespan compared to those without the mutation. The study also suggested that radiation therapy plus temozolomide may be more effective for patients with mutated IDH.
A new study by Ohio State University Wexner Medical Center found a low risk of life-threatening cardiac events among patients with chest pain who have normal test results. The researchers suggest discharging these patients to outpatient settings for further testing, which could significantly reduce hospital admissions.
A new study at Ohio State University has identified Foxo1 as a negative regulator of natural killer cell maturation and homing behavior. The findings suggest that reducing Foxo1 expression can enhance NK-cell maturation, providing an opportunity to boost cancer and viral immunity.
A 24-week parent training study by Ohio State University Wexner Medical Center significantly reduced disruptive behavior in children with autism. The study showed that parent training was more effective in reducing behavior problems than parent education, with 70% of children showing a positive response.
A new study published in JCAP found that adding risperidone to parent training improved teachers' assessments of anxiety and social avoidance. Children who showed reduced anxiety also displayed less disruptive behavior, contributing to a reduction in aggressive symptoms.
A new scoring method called MATH measures genetic variability among cancer cells within tumors from patients with head and neck cancer. High MATH scores correspond to tumors with many differences among gene mutations present in different cancer cells, correlating with lower patient survival.
A protein called MG53 is necessary for the repair of injured kidney cells, according to a study published in Science Translational Medicine. The discovery could lead to new preventive or therapeutic treatments for acute kidney failure, which affects over 30 million Americans.
A new study finds that carotid baroreflex activation therapy (BAT) improves NYHA Class, quality of life scores and exercise capacity in symptomatic advanced heart failure patients receiving optimum drug therapy. BAT was safely implanted with few complications and no adverse effects.
The NCCN Clinical Practice Guidelines in Oncology provide evidence-based recommendations for smoking cessation in patients with cancer. Combining pharmacologic therapy and counseling is the most effective approach, leading to improved cancer treatment effectiveness and decreased recurrence.
A new study has identified a group of molecules in prostate-cancer cells that can help distinguish which patients should be treated with radiation therapy if rising PSA levels indicate tumor recurrence. MicroRNA patterns, including miR-4516 and miR-601, may predict patient response to radiation therapy.
A phase II study shows patients with high-risk low-grade gliomas have a 73% three-year overall survival rate when treated with radiation and temozolomide, compared to 54% for historical controls. The findings suggest combining chemotherapy with radiation is the best treatment for these rare tumors.
A study published in JAMA Oncology found that 10% of CLL patients discontinued ibrutinib therapy due to disease progression. Patients who experienced Richter's transformation or progressive CLL had poorer outcomes and required alternative therapy quickly after discontinuation.
Researchers at Ohio State University identified three genes that enable glioblastoma stem-like cells to survive radiation therapy. MELK and EZH2 proteins form a complex that drives EZH2 expression, promoting tumor development and progression.
Researchers at Ohio State University found that androgen receptor activates different genes when bound to antiandrogens, suggesting new targets for prostate cancer treatment. Antiandrogen response elements were discovered, which activate oncogenes relevant to tumor progression.
A new study suggests that dopamine can prevent the growth of blood vessels in tumors without causing serious side effects, unlike existing anti-angiogenic drugs. Dopamine also prevents low neutrophil counts induced by chemotherapy, making it a potential alternative for gastrointestinal cancer treatment.
Researchers at Ohio State University found that patterns of molecules called long noncoding RNAs can predict response to chemotherapy and overall survival in older patients with acute myeloid leukemia. The study identified a group of 48 lncRNAs associated with survival, allowing for personalized treatment approaches.
A study by Ohio State University researchers found that patients treated at highly-experienced radiation oncology centers had better survival rates and fewer cancer recurrences compared to those treated at less experienced centers. The study analyzed data from 470 patients treated with radiation therapy between 2002-2005.
Researchers at Ohio State University have discovered a promising therapy combining an oncolytic virus with doxorubicin to treat advanced or recurrent ovarian cancer. The treatment showed significant antitumor activity in animal models, increasing survival and inducing programmed cell death in cancer cells.
Researchers found that erlotinib, a targeted drug for advanced-stage lung cancer, can increase the aggressiveness of tumors in early-stage patients, leading to accelerated growth and decreased survival rates. The study suggests combining an EGFR inhibitor with a Notch inhibitor may overcome this effect.
Researchers found a potential link between inherited BRCA1 and BRCA2 mutations and increased risk of salivary gland cancer. The study suggests that people with these gene mutations may require earlier evaluation for salivary gland lesions.
Researchers found that nuclear factor kappa B (NF-kB) enables cancer cells to evade the immune system by suppressing genes that inhibit the immune response. Inhibiting NF-kB may make tumor cells more vulnerable to elimination by the immune system.
Two new peptide vaccines and two peptide inhibitors targeting HER-3 and IGF-1R receptors have been developed by Ohio State Researchers. The studies show that combining these agents can boost effectiveness and prevent drug resistance, leading to improved response rates and durable remissions for various types of cancer.
Researchers found that combining low doses of bortezomib with an oncolytic virus significantly improves the ability to kill cancer cells. The combination treatment suppressed tumor growth by 92% in a glioma model and improved survival rates, offering a novel therapeutic strategy for solid tumors.
A phase 3 study found that ibrutinib significantly lengthened progression-free survival as a second-line therapy for CLL, with 86% of patients on ibrutinib experiencing durable responses. Ibrutinib also showed superior results compared to ofatumumab in terms of overall survival and partial response rates.
A new study has discovered how ibrutinib resistance develops in CLL patients, identifying key gene mutations that weaken the drug's ability to bind with Bruton's tyrosine kinase. This understanding is crucial for developing effective alternative treatments for patients who develop resistance.